# of Displayed Technologies: 20 / 53


Categories

Ultra-high-throughput sequencing approach enabling whole-community COVID-19 screening
TS-050647 — REMBRANDT: a high-throughput Next Generation Sequencing-based approach for the simultaneous screening of over 100,000 COVID-19 samples per day.
The Need The SARS-CoV-2 virus, which causes COVID-19 syndrome, has rapidly spread throughout the world and was recently classified by the WHO as a pandemic pathogen. Severe disease that requires hospital admission occurs in 20% of cases, and a subset of these patients require ICU care; the death ra…
  • College: College of Medicine (COM)
  • Inventors: Palmieri, Dario; Fishel, Richard; Miles, Wayne; Siddiqui, Jalal "Jalal"
  • Licensing Officer: Ezzell, Janel

Novel acellular vaccine for protection against Bordetella infection
TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…
  • College: College of Medicine (COM)
  • Inventors: Deora, Rajendar; Mishra, Meenu; Sukumar, Neelima
  • Licensing Officer: Ezzell, Janel

Method for diagnosis and prognosis of Alzheimer's disease
TS-050046 — Methods using miRNAs for early Alzheimer’s Disease diagnoses and altered expression of key autophagy related proteins
The Need Alzheimer’s Disease (AD) is the most common cause of age-related dementia leading to severe and irreversible neurodegeneration and cognitive decline. Currently, AD has no cure or effective preventive approaches. Using current diagnostic techniques, AD cannot be clinically diagnosed b…
  • College: College of Medicine (COM)
  • Inventors: Amer, Amal
  • Licensing Officer: Flammang, Ann Marie

Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
  • College: College of Medicine (COM)
  • Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
  • Licensing Officer: Ezzell, Janel

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: Ezzell, Janel

An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-targeting activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases such as Duchenne muscular dystrophy (DMD) lacking effective therapeutic treatments. DMD is caused by genetic mutations in the DMD gene, which encodes the dystrophin protein. The mutations including missense point mutations, nonsense point mutations, deleti…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Davis, Stewart

Nras Mouse Melanoma Cell Lines
TS-049491 — Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that can be used for preclinical tumor immunology and cancer biology studies.
Studies show that 15-30% of melanomas are Nras driven and 60% of melanomas are Braf driven. Dr. Christin Burd's lab at The Ohio State University has developed a set of Nras-mutant mouse melanoma cell lines that complement a set of Braf cell lines developed by Marcus Bosenberg at Yale Universit…
  • College: College of Medicine (COM)
  • Inventors: Burd, Christin; Murphy, Brandon
  • Licensing Officer: Davis, Stewart

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Ezzell, Janel

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: Ezzell, Janel

Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang; Hodgetts, Kevin
  • Licensing Officer: Dahlman, Jason "Jay"

Targeting β-catenin signaling in combination with EGFR TKI enhances progression free survival and overall survival of EGFR mutant NSCLC
TS-042666 — The discovery of a novel treatment for EGFR TKI drug resistance in NSCLC.
Non-small cell lung cancer (NSCLC), which accounts for 85% of all lung cancers, is one of the leading causes of cancer-related death. Substantial progress has been made in the management of NSCLC as several driver mutations have been identified in cell communication pathways involved in lung tumor…
  • College: College of Medicine (COM)
  • Inventors: Arasada, Rajeswara Rao; Carbone, David
  • Licensing Officer: Davis, Stewart

High-strength and Corrosion Resistant Alloy for Patient-Specific Bioresorbable Bone Fixation Hardware
TS-042526 — Novel ternary and quaternary Mg-Zn-Ca-based alloys and a heat treatment process for producing bioresorbable bone fixation implants with improved mechanical and corrosion properties
Mg-Zn-Ca-based alloys are the most promising alloy system for bone implant applications mainly due to their superior biocompatibility. For fixation applications, the ideal is a material strong enough to hold while healing (2-4 months) yet being fully resorbed after the bones have healed (6-24 mont…
  • College: College of Medicine (COM)
  • Inventors: Dean, David; Elahinia, Mohammad; Ibrahim, Hamdy
  • Licensing Officer: Norris, Francis "Frank"

Papaverine Derivatives that are Effective Hypoxic Tumor Radiosensitizers
TS-041504 — Dr. Nicholas Denko and colleagues at The Ohio State University have developed papaverine derivatives that can be used as metabolic radiosensitizers in hypoxic tumors. The compounds make cancer cells more sensitive to radiation therapy without the concomitant toxicity issues that can occur as a side-effect of papaverine.
Radiation therapy is a common treatment for cancerous tumors. However, environmental conditions in the tumor can influence sensitivity to radiation therapy, and some cells are resistant to treatment. For example, hypoxic cells (those with low levels of oxygen) in tumors such as lung, glioblastoma,…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Mitton-Fry, Mark; Papandreou, Ioanna; Vibhute, Sandip
  • Licensing Officer: Davis, Stewart

Identifying the level of lupus patients’ comprehension of their medication regimens and disease outcomes
TS-040132 — A questionnaire used to understand a patient’s comprehension of their personalized medication plan and the disease fluctuation of systemic lupus erythematous (SLE).
Systemic lupus erythematous (SLE) is an autoimmune disease in which the body’s immune system attacks healthy tissue in its own body. The disease has a prevalance of twenty to 150 cases per 100,000 individuals, and is more common in females than in men. This chronic disease has no cure, and s…
  • College: College of Medicine (COM)
  • Inventors: Meara, Alexa; Ardoin, Stacy; Peters, Ellen
  • Licensing Officer: Davis, Stewart

Virtual image generation of immunohistochemical stained tissue sections using an artificial neural network
TS-039781 — Realistic immunohistochemical stained tissue section databases for training, certification, and machine standards.
Immunohistochemistry (IHC) is used to determine antigen distribution in a tissue and is widely used for diagnosis of cancers and other diseases. Diagnostic and research laboratories in the United States use locally devised IHC tissue slide preparation and scanning protocols to check scanner perfor…
  • College: College of Medicine (COM)
  • Inventors: Gurcan, Metin; Lozanski, Gerard; Senaras, Caglar
  • Licensing Officer: Norris, Francis "Frank"

Automated Detection of Tumor Budding in Colorectal Cancer
TS-039267 — A non-invasive and automated tumor budding image analysis system for colorectal cancer. This program can detect tumor buds in traditional H&E stained sections without the need for manual assessment.
Colorectal cancer is the third most commonly diagnosed cancer in the United States. With a survival rate of less than 65%, early detection and treatment are key factors in survival. Tumor budding, associated with higher tumor stage, lymph node metastasis, and decreased disease-free survival, has e…
  • College: College of Medicine (COM)
  • Inventors: Gurcan, Metin; Ahmad Fauzi, Mohammad Faizal; Chen, Wei "Wei"; Frankel, Wendy
  • Licensing Officer: Norris, Francis "Frank"

Perivascular Drug Delivery Nanoplatform for Preventing Restenosis After Open Surgery
TS-039004 — Pericelle: a nanoparticle based perivascular drug delivery system to prevent stenosis and failure in vascular reconstruction surgeries
Imaging and re-intervention procedures, necessary to maintain open blood vessels following vascular reconstruction surgery, are expensive. For example, the cost of maintenance for an atriovenous (AV) fistula used in hemodialysis access has been estimated at near a staggering $15,000/year. In bypas…
  • College: College of Medicine (COM)
  • Inventors: Kent, K. Craig; Chen, Guojun; Gong, Shaoqin; Guo, Lianwang; Shi, Xudong
  • Licensing Officer: Norris, Francis "Frank"

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: Flammang, Ann Marie

Digital Analysis and Lesion Segmentation Software for Tele-Dermatology
TS-038429 — An automated image analysis system for the recognition and quantification of skin disease.
Acne and rosacea are skin diseases that affect around 85% of individuals. There is no gold standard for evaluation of these skin diseases, and their treatment efficacy is generally determined according to a poorly validated counting process by the physician and patient. This process is prone to po…
  • College: College of Medicine (COM)
  • Inventors: Kaffenberger, Benjamin; Gurcan, Metin
  • Licensing Officer: Ezzell, Janel

Methods for generation of TF-targeting chimeric antigen receptors (CARs)-natural killer cells and T cells
TS-038262 — A therapeutic application of neovascular-targeting chimeric antigen receptor (CAR) T cells and NK cells for treating diseases associated with pathological angiogenesis, in which TF is abarrently expressed, such as solid tumors, leukemia, lymphoma, age-related macular degeneration (AMD), endometriosis, and rheumatoid arthritis.
Nearly 2,000,000 new cancer cases are expected to be diagnosed each year in the United States. Available treatment options include surgery, radiation therapy, chemotherapy, and immunotherapy. Recently, cell-based immunotherapy utilizing specific chimeric antigen receptor (CAR) expressing immune ce…
  • College: College of Medicine (COM)
  • Inventors: Hu, Zhiwei
  • Licensing Officer: Flammang, Ann Marie

Show More Technologies

Loading icon